Cercar

01/11/2024 Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Casanova, MJ, Caballol, B, García, MJ, Mesonero, F, de Célix, CR, Suárez-Alvarez, P, Ferreiro-Iglesias, R, Martín-Rodríguez, MDM, de Francisco, R, Varela-Trastoy, P, Bastida, G, Carrillo-Palau, M, Núñez-Ortiz, A, Ramírez-de la Piscina, P, Ceballos, D, Hervías-Cruz, D, Muñoz-Pérez, R, Velayos, B, Bermejo, F, Busquets, D, Cabacino, M, Camo-Monterde, P, Marín-Jiménez, I, Muñoz, C, de la Peña-Negro, LC, Sierra-Moros, E, Barrio, J, Brunet-Mas, E, Bujanda, L, Cañete, F, Gomollón, F, Manceñido-Marcos, N, Rodríguez-Lago, I, Rodríguez-Grau, MC, Sicilia, B, Torra-Alsina, S, Arranz-Hernández, L, Carpio, D, García-Sepulcre, MF, González-Muñoza, C, Huguet, JM, Márquez-Mosquera, L, López-Serrano, MP, Ponferrada-Díaz, A, Chaparro, M, Gisbert, JP. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU. DIGESTIVE AND LIVER DISEASE. 2024; 56(11)DOI:10.1016/j.dld.2024.05.009. PMID:38839456. IF:3.800(Q2/3D).
01/10/2024 Examining the therapeutic landscape of beta-blockers in portal hypertension
Brujats, A, Villanueva, C. Examining the therapeutic landscape of beta-blockers in portal hypertension. Clinical and Molecular Hepatology. 2024; 30(4)DOI:10.3350/cmh.2024.0144. PMID:38447532. IF:16.900(Q1/1D).
01/10/2024 Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient
Olivas, P, Soler-Perromat, A, Tellez, L, Carrion, JA, Alvarado-Tapias, E, Ferrusquia-Acosta, J, Lens, S, Guerrero, A, Falga, A, Vizcarra, P, Orts, L, Perez-Campuzano, V, Shalaby, S, Torres, S, Baiges, A, Turon, F, Garcia-Pagan, JC, Garcia-Criado, A, Hernandez-Gea, V. Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient. Jhep Reports. 2024; 6(10)DOI:10.1016/j.jhepr.2024.101170. PMID:39430576. IF:7.500(Q1/2D).
01/10/2024 THE GLOBAL PROFILE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): CLINICAL PRESENTATION, HISTOLOGIC STAGE, NON-INVASIVE TESTS AND MORTALITY FROM THE GLOBAL NAFLD/MASLD REGISTRY
Younossi, Z, Alkhouri, N, Hagström, H, Kim, SU, Crespo, J, Castera, L, Zheng, MH, Treeprasertsuk, S, Shalimer, D, Alswat, K, Fan, JG, Roberts, S, Tsochatzis, E, Dunn, W, Wong, V, Yilmaz, Y, Francque, S, de Oliveira, C, Pessoa, MG, Ekstedt, M, Goh, GBB, Duseja, A, Chan, WK, Fernandez, MIC, Sebastiani, G, Lampertico, P, Alnaamani, K, Valsan, AK, Holleboom, AG, El-Kassas, M, Choudhary, NS, Vessby, J, Singal, A, Kakizaki, S, Pearlman, B, Gunn, N, Cordie, A, Mauricio, D, Kawaguchi, T, Nadeem, R, Shang, Y, Lee, HW, Iruzubieta, P, Liu, WY, Ananchuensook, P, Yang, RX, Zoncapé, M, Dunn, N, Song, SJ, Gadi, Z, Teh, KKJ, Mahadeva, S, Fabian, LG, Cinque, F, D'Ambrosio, R, Friend, E, Poca, M, Colombu, M, Allen, A, Lazarus, J, Lam, B, de Avila, L, Racila, A, Alqahtani, S, Stepanova, M. THE GLOBAL PROFILE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): CLINICAL PRESENTATION, HISTOLOGIC STAGE, NON-INVASIVE TESTS AND MORTALITY FROM THE GLOBAL NAFLD/MASLD REGISTRY. HEPATOLOGY. 2024; 80DOI:. PMID:. IF:15.800(Q1/1D).
01/09/2024 An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial
Ortiz, O, Daca-Alvarez, M, Rivero-Sanchez, L, Gimeno-Garcia, AZ, Carrillo-Palau, M, Alvarez, V, Ledo-Rodriguez, A, Ricciardiello, L, Pierantoni, C, Hüneburg, R, Nattermann, J, Bisschops, R, Tejpar, S, Huerta, A, Pons, FR, Alvarez-Urturi, C, López-Vicente, J, Repici, A, Hassan, C, Cid, L, Cavestro, GM, Romero-Mascarell, C, Gordillo, J, Puig, I, Herraiz, M, Betes, M, Herrero, J, Jover, R, Balaguer, F, Pellisé, M. An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial. Lancet Gastroenterology & Hepatology. 2024; 9(9)DOI:10.1016/S2468-1253(24)00187-0. PMID:39033774. IF:38.600(Q1/1D).
01/08/2024 Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease
Brujats, A, Huerta, A, Osuna-Gómez, R, Guinart-Cuadra, A, Ferrero-Gregori, A, Pujol, C, Soriano, G, Poca, M, Fajardo, J, Escorsell, A, Gallego, A, Vidal, S, Villanueva, C, Alvarado-Tapias, E. Immune Response and Risk of Decompensation following SARS-CoV-2 Infection in Outpatients with Advanced Chronic Liver Disease. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(15)DOI:10.3390/ijms25158302. PMID:39125872. IF:4.900(Q1/3D).
01/07/2024 Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Ruiz-Cobo, JC, Llaneras, J, Forns, X, Moya, AG, Amiel, IC, Arencibia, A, Diago, M, Garcia-Samaniego, J, Castellote, J, Llerena, S, Rodriguez-Seguel, E, Mateos, B, Rodriguez, M, Zabal, JMR, Fernandez, I, Calleja, JL, Morillas, RM, Montoliu, S, Andrade, RJ, Aranda, EB, Hernandez-Guerra, M, Mate, CJ, Gonzalez-Santiago, JM, de Cuenca, B, Bernal-Monterde, V, Delgado, M, Turnes, J, Lens, S, Buti, M. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2024; 60(2)DOI:10.1111/apt.18020. PMID:38695095. IF:6.700(Q1/1D).
28/06/2024 Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
Ferreiro-Iglesias, R, Silva, SP, Marín, S, Casanova, MJ, Mañosa, M, González-Muñoza, C, de Francisco, R, Caballol, B, Arias, L, Piqueras, M, Zabana, Y, Rivero, M, Calvet, X, Mesonero, F, Trastoy, PV, Nistal, RB, Perosanz, RG, Vega, P, Gonzalez-Vivo, M, Iborra, M, Bermejo, F, Madero, L, Rodríguez-Lago, I, Gonzalez, MR, Vera, I, Díaz, AP, Vela, M, Medina, LT, Van Domselaar, M, Gomollón, F, Iglesias, E, Gisbert, JP, Calafat, M, Giordano, A, Pérez-Martínez, I, Ricart, E, Sicilia, B, Mena, R, Esteve, M, Rivas, C, Brunet-Mas, E, Fernández, C, Turrión, MAD, Jiménez, BV, Calvo, MQ, Expósito, CR, Márquez-Mosquera, L, Nos, P, Granja, A, Gutiérrez, A, Cabriada, JL, Cruz, DH, Calvo, M, Pérez, JP, Díaz, YR, Casal, DB, Menacho, M, Leal, C, Lucendo, AJ, Royo, V, Olivares, S, Herrero, BA, Carrillo-Palau, M, Alvarez, PG, Marcos, NM, Martínez-Pérez, TD, Villafranca, MCM, Almela, P, Argüelles-Arias, F, Legido, J, Coronel, AMF, Nieto, L, Domènech, E, Acosta, MBD. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2024; 60(5)DOI:10.1111/apt.18133. PMID:38943230. IF:6.700(Q1/1D).